Home > Cardiology > More-intensive statin-based therapies may be warranted for secondary stroke prevention

More-intensive statin-based therapies may be warranted for secondary stroke prevention


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Neurology
Reuters Health - 23/02/2022 - More-intensive LDL cholesterol-lowering statin-based therapies may be warranted in patients with ischemic stroke and atherosclerosis, researchers behind a new meta-analysis suggest.  In clinical trials, compared with statins alone, statins plus cholesterol-absorption inhibitors (ezetimibe) or PCSK9 inhibitors (alirocumab or evolocumab) lowered the number of major cardiovascular events and strokes for patients with a history of acute coronary syndrome or atherosclerotic cardiovascular disease.  However, it's unclear whether ezetimibe or PCSK9 inhibitors are beneficial when added to statins in patients with prior stroke.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on